Award winner of the Fonds Santé —
PhD student in Biochemistry at McGill University
Published in Cancer Research, 72(5), March 1, 2012, pages1270-1279.
“We identified a novel mechanism through which the p53 tumor suppressor gene inhibits angiogenesis. We demonstrated that p53 directly upregulates the expression of α1 collagen IV and increases the secretion of Arresten, an anti-angiogenic factor derived from α1 collagen IV. The upregulation of Arresten led to a significant inhibition of angiogenesis and tumor growth in vivo. We also observed a correlation between p53 and Arresten staining in human prostate cancer specimens, thus validating our results in human tumors.”
Identification of endogenous anti-angiogenic factors and increasing understanding of their function can have significant impact on the development of novel anti-angiogenic therapies. Prostate cancers with p53 mutations are a highly aggressive subgroup of tumors with a high risk of progression. Identification of these aggressive subtypes at an early stage would have significant impact on a patient’s life, as more aggressive therapeutic measures may be adopted to attack the tumor before it progresses, and Arresten may prove to be useful in doing so.